Targeting cardiovascular risk in patients with diabetes: Management of dyslipidemia

Yasmine S. Ali, MacRae F. Linton, Sergio Fazio

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: The management of dyslipidemia in patients with diabetes is a key component of cardiovascular risk reduction. In particular, the atherogenic dyslipidemia of diabetes often requires combination therapy to target aspects of the lipid profile beyond low-density lipoprotein cholesterol. This article will review the characteristics of dyslipidemia in diabetes, and discuss guidelines and strategies for treatment to reduce cardiovascular disease risk. RECENT FINDINGS: A number of clinical outcomes trials supports the use of statins to reduce cardiovascular events in patients with type 2 diabetes mellitus. The disappointing results of clinical trials involving torcetrapib to increase high-density lipoprotein levels may lead to renewed interest and utilization of niacin for the management of atherogenic dyslipidemia. Long-term use of fibrate therapy in patients with atherogenic dyslipidemia has recently been associated with reduction in all-cause, cancer, and cardiovascular mortality rates. Ongoing trials are investigating whether addition of niacin or fibrate to statin therapy is superior to statin therapy alone in preventing cardiovascular events. SUMMARY: Aggressive low-density lipoprotein control continues to be the primary goal of therapy in dyslipidemia management. Given the growing body of evidence showing the cardiovascular benefits of treating other lipid components, however, it is easy to anticipate that full normalization of the lipid profile may become the standard of care for diabetic dyslipidemia.

Original languageEnglish (US)
Pages (from-to)142-146
Number of pages5
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Volume15
Issue number2
DOIs
StatePublished - Apr 2008
Externally publishedYes

Fingerprint

Dyslipidemias
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Fibric Acids
Niacin
Lipids
Therapeutics
Clinical Trials
Risk Reduction Behavior
HDL Lipoproteins
Standard of Care
LDL Lipoproteins
LDL Cholesterol
Type 2 Diabetes Mellitus
Cardiovascular Diseases
Guidelines
Mortality
Neoplasms

Keywords

  • Atherogenic lipid triad
  • Cardiovascular risk
  • Diabetes
  • Dyslipidemia

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics
  • Medicine(all)

Cite this

Targeting cardiovascular risk in patients with diabetes : Management of dyslipidemia. / Ali, Yasmine S.; Linton, MacRae F.; Fazio, Sergio.

In: Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 15, No. 2, 04.2008, p. 142-146.

Research output: Contribution to journalArticle

@article{af64c4d89b474e1ca074813f8249151e,
title = "Targeting cardiovascular risk in patients with diabetes: Management of dyslipidemia",
abstract = "PURPOSE OF REVIEW: The management of dyslipidemia in patients with diabetes is a key component of cardiovascular risk reduction. In particular, the atherogenic dyslipidemia of diabetes often requires combination therapy to target aspects of the lipid profile beyond low-density lipoprotein cholesterol. This article will review the characteristics of dyslipidemia in diabetes, and discuss guidelines and strategies for treatment to reduce cardiovascular disease risk. RECENT FINDINGS: A number of clinical outcomes trials supports the use of statins to reduce cardiovascular events in patients with type 2 diabetes mellitus. The disappointing results of clinical trials involving torcetrapib to increase high-density lipoprotein levels may lead to renewed interest and utilization of niacin for the management of atherogenic dyslipidemia. Long-term use of fibrate therapy in patients with atherogenic dyslipidemia has recently been associated with reduction in all-cause, cancer, and cardiovascular mortality rates. Ongoing trials are investigating whether addition of niacin or fibrate to statin therapy is superior to statin therapy alone in preventing cardiovascular events. SUMMARY: Aggressive low-density lipoprotein control continues to be the primary goal of therapy in dyslipidemia management. Given the growing body of evidence showing the cardiovascular benefits of treating other lipid components, however, it is easy to anticipate that full normalization of the lipid profile may become the standard of care for diabetic dyslipidemia.",
keywords = "Atherogenic lipid triad, Cardiovascular risk, Diabetes, Dyslipidemia",
author = "Ali, {Yasmine S.} and Linton, {MacRae F.} and Sergio Fazio",
year = "2008",
month = "4",
doi = "10.1097/MED.0b013e3282f5ff98",
language = "English (US)",
volume = "15",
pages = "142--146",
journal = "Current Opinion in Endocrinology, Diabetes and Obesity",
issn = "1752-296X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Targeting cardiovascular risk in patients with diabetes

T2 - Management of dyslipidemia

AU - Ali, Yasmine S.

AU - Linton, MacRae F.

AU - Fazio, Sergio

PY - 2008/4

Y1 - 2008/4

N2 - PURPOSE OF REVIEW: The management of dyslipidemia in patients with diabetes is a key component of cardiovascular risk reduction. In particular, the atherogenic dyslipidemia of diabetes often requires combination therapy to target aspects of the lipid profile beyond low-density lipoprotein cholesterol. This article will review the characteristics of dyslipidemia in diabetes, and discuss guidelines and strategies for treatment to reduce cardiovascular disease risk. RECENT FINDINGS: A number of clinical outcomes trials supports the use of statins to reduce cardiovascular events in patients with type 2 diabetes mellitus. The disappointing results of clinical trials involving torcetrapib to increase high-density lipoprotein levels may lead to renewed interest and utilization of niacin for the management of atherogenic dyslipidemia. Long-term use of fibrate therapy in patients with atherogenic dyslipidemia has recently been associated with reduction in all-cause, cancer, and cardiovascular mortality rates. Ongoing trials are investigating whether addition of niacin or fibrate to statin therapy is superior to statin therapy alone in preventing cardiovascular events. SUMMARY: Aggressive low-density lipoprotein control continues to be the primary goal of therapy in dyslipidemia management. Given the growing body of evidence showing the cardiovascular benefits of treating other lipid components, however, it is easy to anticipate that full normalization of the lipid profile may become the standard of care for diabetic dyslipidemia.

AB - PURPOSE OF REVIEW: The management of dyslipidemia in patients with diabetes is a key component of cardiovascular risk reduction. In particular, the atherogenic dyslipidemia of diabetes often requires combination therapy to target aspects of the lipid profile beyond low-density lipoprotein cholesterol. This article will review the characteristics of dyslipidemia in diabetes, and discuss guidelines and strategies for treatment to reduce cardiovascular disease risk. RECENT FINDINGS: A number of clinical outcomes trials supports the use of statins to reduce cardiovascular events in patients with type 2 diabetes mellitus. The disappointing results of clinical trials involving torcetrapib to increase high-density lipoprotein levels may lead to renewed interest and utilization of niacin for the management of atherogenic dyslipidemia. Long-term use of fibrate therapy in patients with atherogenic dyslipidemia has recently been associated with reduction in all-cause, cancer, and cardiovascular mortality rates. Ongoing trials are investigating whether addition of niacin or fibrate to statin therapy is superior to statin therapy alone in preventing cardiovascular events. SUMMARY: Aggressive low-density lipoprotein control continues to be the primary goal of therapy in dyslipidemia management. Given the growing body of evidence showing the cardiovascular benefits of treating other lipid components, however, it is easy to anticipate that full normalization of the lipid profile may become the standard of care for diabetic dyslipidemia.

KW - Atherogenic lipid triad

KW - Cardiovascular risk

KW - Diabetes

KW - Dyslipidemia

UR - http://www.scopus.com/inward/record.url?scp=42449114912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449114912&partnerID=8YFLogxK

U2 - 10.1097/MED.0b013e3282f5ff98

DO - 10.1097/MED.0b013e3282f5ff98

M3 - Article

C2 - 18316949

AN - SCOPUS:42449114912

VL - 15

SP - 142

EP - 146

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

SN - 1752-296X

IS - 2

ER -